Evidence map›Paper›PMID 19383116›Full record

ArticleBMC family practice2009

Reasons of general practitioners for not prescribing lipid-lowering medication to patients with diabetes: a qualitative study.

Elisabeth AB, Petra Denig, Ton van Vliet, Janny H Dekker

Full text read
In one paragraph

Article in BMC family practice, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Barriers to effective management of type 2 diabetes in primary care: qualitative systematic review.The British journal of general practice : the journal of the Royal College of General Practitioners · 2016
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Impact of lowering the risk threshold for statin treatment on statin prescribing: a descriptive study in English primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2020
    Article
  10. Article
  11. Article
  12. Observational
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elisabeth ABDepartment of Clinical Pharmacology, University Medical Centre Groningen, University of Groningen, Groningen, The Netherlands. liesbeth.ab@planet.nl
Petra Denig
Ton van Vliet
Janny H Dekker

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLipid-lowering medication remains underused, even in high-risk populations. The objective of this study was to determine factors underlying general practitioners' decisions not to prescribe such drugs to patients with type 2 diabetes.

methodsA qualitative study with semi-structured interviews using real cases was conducted to explore reasons for not prescribing lipid-lowering medication after a guideline was distributed that recommended the use of statins in most patients with type 2 diabetes. Seven interviews were conducted with general practitioners (GPs) in The Netherlands, and analysed using an analytic inductive approach.

resultsReasons for not-prescribing could be divided into patient and physician-attributed factors. According to the GPs, some patients do not follow-up on agreed medication and others object to taking lipid-lowering medication, partly for legitimate reasons such as expected or perceived side effects. Furthermore, the GPs themselves perceived reservations for prescribing lipid-lowering medication in patients with short life expectancy, expected compliance problems or near goal lipid levels. GPs sometimes postponed the start of treatment because of other priorities. Finally, barriers were seen in the GPs' practice organisation, and at the primary-secondary care interface.

conclusionSome of the barriers mentioned by GPs seem to be valid reasons, showing that guideline non-adherence can be quite rational. On the other hand, treatment quality could improve by addressing issues, such as lack of knowledge or motivation of both the patient and the GP. More structured management in general practice may also lead to better treatment.

Indexed as

Practice Patterns, Physicians'AdultAttitude of Health PersonnelDiabetes Mellitus, Type 2FemaleGuideline AdherenceHumansHydroxymethylglutaryl-CoA Reductase InhibitorsHyperlipidemiasInterviews as TopicMaleMiddle AgedPatient CompliancePhysicians, FamilyQualitative ResearchHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID19383116
PMCPMC2676243

What OpenQuestion holds

Textfull text, public
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.